Understanding the effect of repeated administration of meloxicam on feline renal cortex and medulla: A lipidomics and metabolomics approach. Issue 4 (12th June 2019)

• Record Type: Journal Article
• Authors: Rivera‐Velez, Sol M.; Broughton‐Neiswanger, Liam E.; Suarez, Martin A.; Slovak, Jennifer E.; Hwang, Julianne K.; Navas, Jinna; Leung, Amy W. S.; Piñeyro, Pablo E.; Villarino, Nicolas F.
• Is Part Of: Journal of veterinary pharmacology and therapeutics. Volume 42:Issue 4(2019)
• Page Start: 476
• Page End: 486
• Publication Date: 2019-06-12
• Subjects: cats -- kidney -- meloxicam -- metabolomics -- NSAIDs; Veterinary pharmacology -- Periodicals; Therapeutics -- Periodicals; 636.0895105
• DOI: 10.1111/jvp.12788
• Languages: English
• ISSNs: 0140-7783

Abstract

Abstract: Repeated administration of meloxicam can cause kidney damage in cats by mechanisms that remain unclear. Metabolomics and lipidomics are powerful, noninvasive approaches used to investigate tissue response to drug exposure. Thus, the objective of this study was to assess the effects of meloxicam on the feline kidney using untargeted metabolomics and lipidomics approaches. Female young‐adult purpose‐breed cats were allocated into the control ( n = 4) and meloxicam ( n = 4) groups. Cats in the control and meloxicam groups were treated daily with saline and meloxicam at 0.3 mg/kg subcutaneously for 17 days, respectively. Renal cortices and medullas were collected at the end of the treatment period. Random forest and metabolic pathway analyses were used to identify metabolites that discriminate meloxicam‐treated from saline‐treated cats and to identify disturbed metabolic pathways in renal tissue. Our results revealed that the repeated administration of meloxicam to cats altered the kidney metabolome and lipidome and suggest that at least 40 metabolic pathways were altered in the renal cortex and medulla. These metabolic pathways included lipid, amino acid, carbohydrate, nucleotide and energy metabolisms, and metabolism of cofactors and vitamins. This is the first study using a pharmacometabonomics approach for studying the molecular effects of meloxicam on feline kidneys.